A clear, evidence-based comparison of Bundibugyo virus and Zaire ebolavirus — case fatality rate, transmission dynamics, glycoprotein biology, and why the licensed Zaire-derived vaccines and monoclonal antibodies are not expected to work against the 2026 DRC Bundibugyo strain.
Bundibugyo virus and Zaire ebolavirus are two of four orthoebolavirus species known to cause Ebola disease in humans. They differ at the genome level and most importantly at the surface glycoprotein that drives cell entry. Those structural differences carry direct operational consequences for the response. The 2026 DRC + Uganda Bundibugyo outbreak runs at a meaningfully lower case fatality rate than Zaire ebolavirus would, but the licensed Zaire-specific vaccine (Ervebo) and monoclonal-antibody therapeutics (Inmazeb, Ebanga) are not expected to protect against or treat Bundibugyo virus disease. The WHO R&D Blueprint has prioritised two Bundibugyo-specific or pan-orthoebolavirus monoclonal antibodies for clinical trial and obeldesivir for post-exposure prophylaxis assessment.
| Species | First described | Published CFR | Geography | Licensed vaccine/treatment? |
|---|---|---|---|---|
| Zaire ebolavirus (EBOV) | 1976 (DRC) | Up to 90% untreated, ~40% with care | West and Central Africa | Ervebo, Inmazeb, Ebanga |
| Sudan ebolavirus (SUDV) | 1976 (Sudan) | 40-65% | Uganda, Sudan | None (candidate vaccines in trial) |
| Bundibugyo virus (BDBV) | 2007 (Uganda) | 25-40% historically; ~10% in 2026 confirmed | Uganda, DRC | None — WHO R&D pipeline active |
| Tai Forest ebolavirus (TAFV) | 1994 (Ivory Coast) | Single non-fatal human case | Ivory Coast, Liberia | None |
The published case fatality rate of Bundibugyo virus, at roughly 25 to 40 percent depending on outbreak setting, is meaningfully lower than the Zaire ebolavirus CFR of up to 90 percent in untreated outbreaks. The 2026 DRC cluster currently sits at approximately 10 percent CFR for PCR-confirmed cases (11 confirmed deaths against 106 cumulative confirmed cases), reflecting both the underlying biology and the rapid clinical-management response. The published evidence suggests the CFR difference between Bundibugyo and Zaire is at least partly biological rather than purely a function of care quality. Bundibugyo virus has a slightly less efficient cell-entry glycoprotein, somewhat lower peak viraemia in published primate models, and a slightly slower progression through the prodromal-to-haemorrhagic phase trajectory.
The surface glycoprotein of an orthoebolavirus is the molecule that mediates cell entry — it is the target of neutralising antibodies and the antigen used in vaccine design. The amino-acid sequence identity between Bundibugyo virus glycoprotein and Zaire ebolavirus glycoprotein is roughly 65 to 70 percent — significant overlap but enough divergence at the antigenic epitopes that cross-protective immunity is not guaranteed. The published in-vitro neutralisation data and primate-model cross-challenge experiments suggest some partial cross-protection from Zaire-derived immunity at very high antibody titres, but not enough for the WHO to recommend Zaire vaccines or monoclonal antibodies as standard care against Bundibugyo virus disease.
Ervebo (rVSV-ZEBOV-GP) is the only WHO-prequalified licensed Ebola vaccine. It is highly effective against Zaire ebolavirus — the vaccine's vector carries the Zaire glycoprotein gene, and the antibody response it elicits is centred on Zaire ebolavirus epitopes. The published cross-protection evidence against Bundibugyo is thin and not sufficient to support a policy recommendation. The Sabin Vaccine Institute cAd3-EBOZ candidate and the Janssen two-dose Zabdeno/Mvabea regimen are similarly Zaire-specific. The WHO has not recommended Ervebo, Zabdeno/Mvabea or any other Zaire-derived vaccine for routine use against the 2026 Bundibugyo cluster.
Inmazeb (atoltivimab/maftivimab/odesivimab) is a triple monoclonal-antibody cocktail and Ebanga (ansuvimab) is a single monoclonal antibody. Both target the Zaire ebolavirus surface glycoprotein and were licensed on the basis of efficacy data from the PALM trial run during the 2018-20 DRC Kivu Zaire ebolavirus outbreak. The structural difference at the Bundibugyo glycoprotein means the binding affinity of both monoclonal-antibody products is reduced against the Bundibugyo strain, and the in-vitro and primate-model neutralisation data do not support a clinical efficacy claim. The CDC and WHO clinical guidance for the 2026 cluster does not recommend either as routine therapy.
The WHO Research & Development Blueprint technical advisory group on therapeutics has prioritised two monoclonal antibodies for clinical trial against Bundibugyo virus. The published candidates are early-phase Bundibugyo-specific or pan-orthoebolavirus mAbs from the Mapp Biopharmaceutical and Vanderbilt portfolios. The advisory group has also prioritised the antiviral obeldesivir (the oral prodrug of remdesivir) for post-exposure prophylaxis assessment in high-risk contacts. The trial-readiness timeline is the operational pressure point: WHO and Africa CDC are working with the trial sponsors to mobilise field-trial capacity in the Ituri and North Kivu health zones within weeks rather than months, with the explicit goal of accumulating clinical efficacy data while the cluster is still at scale.
The vaccine and therapeutic gap for the Bundibugyo strain is the single most consequential operational constraint on the 2026 response. Without a licensed Bundibugyo vaccine, the WHO response cannot deploy the ring-vaccination strategy that anchored the recent Zaire ebolavirus DRC responses. Without licensed Bundibugyo-specific monoclonal-antibody therapy, the receiving-country clinical teams are running supportive care plus experimental access protocols rather than a standardised therapeutic. The response geometry therefore relies more heavily on contact tracing, isolation-unit capacity, infection-prevention training for local healthcare workers, and case-finding speed — all of which MSF, CDC, Africa CDC and WHO are actively scaling in the affected DRC health zones.
Bundibugyo virus (BDBV) and Zaire ebolavirus (EBOV) are two of four orthoebolavirus species known to cause human disease. They differ at the genome level and most importantly at the surface glycoprotein that drives cell entry. Those structural differences mean vaccines and monoclonal antibodies developed against Zaire ebolavirus do not necessarily protect against Bundibugyo.
Zaire ebolavirus has a published case fatality rate of up to 90 percent in untreated outbreaks; Bundibugyo virus runs at roughly 25 to 40 percent historically and approximately 10 percent for confirmed cases in the current 2026 cluster. The CFR difference is at least partly biological — Bundibugyo has a slightly less efficient cell-entry glycoprotein and slightly lower peak viraemia in published primate models.
No — Ervebo (rVSV-ZEBOV-GP) is highly effective against Zaire ebolavirus, which provides the glycoprotein component of the vector. Because Bundibugyo has a structurally different surface glycoprotein, the antibody and T-cell immunity Ervebo elicits is not expected to provide meaningful protection against Bundibugyo. WHO has not recommended Ervebo for the 2026 cluster.
Both target the Zaire ebolavirus glycoprotein and were licensed on the basis of Zaire ebolavirus efficacy data. The structural difference in the Bundibugyo glycoprotein means the binding affinity is reduced; the in-vitro and primate-model data do not support routine clinical use against Bundibugyo. Neither is recommended for the 2026 cluster.
The WHO R&D Blueprint technical advisory group has prioritised two Bundibugyo-specific or pan-orthoebolavirus monoclonal antibodies for clinical trial, and the oral antiviral obeldesivir (the prodrug of remdesivir) for post-exposure prophylaxis assessment in high-risk contacts. The trial-readiness timeline is the operational pressure point.
Four orthoebolavirus species are known to cause disease in humans: Zaire, Sudan, Bundibugyo, and Tai Forest (a single non-fatal human case). A fifth species — Reston — circulates in primates and pigs in Asia but has not caused human disease.